停止猜测，开始精准分析
因为每一位患者的情况都是独特的，个性化方案同样应当如此。
通过更深入的生物信息分析，为后续方案选择与持续观察提供参考， 用更清晰的方向支持整体健康管理路径。
为什么考虑液体活检检测
可能具有参考价值
个性化癌症方案可在治疗前提供更多生物信息参考，帮助优化治疗选择与后续规划判断。
| 成本对比 | 参考费用 |
|---|---|
| 液体活检（CTC检测） | US$1,000–US$3,000 |
| 一次无效化疗周期 | US$8,000–US$50,000+ |
| 6个月化疗疗程 | US$27,000–US$150,000+ |
1. 所示费用为参考区间，不同地区、方案及个体情况可能存在差异。
2. 液体活检可作为辅助信息参考，不替代专业临床判断。
用药敏感性报告示例
该图展示了一份实验室用药敏感性分析示例，用于评估癌细胞对不同抗肿瘤方案可能产生的反应情况。
相关结果可作为医生在结合其他临床信息时的参考之一，辅助评估潜在更合适的方案选择，并减少对低效方案的依赖风险。
理解您的精准报告
精准报告在标准临床结果基础上增加生物学层面的参考信息，帮助医生更好地理解风险、筛选相关方案，并进行动态监测，从而辅助治疗决策。
报告可帮助理解的内容
结构化信息可为肿瘤团队提供更清晰的决策参考。
- ✓可参考信号：可能支持治疗选择或方案排序的生物学提示。
- ✓监测参考：用于辅助观察反应变化与趋势。
- ✓风险背景：帮助理解“稳定”或“进展”的生物学含义。
与标准护理的结合方式
| 领域 | 标准护理 | 精准支持 |
|---|---|---|
| 决策依据 | 临床 + 影像 | 临床 + 影像 + 生物信号 |
| 监测方式 | 定期扫描 | 扫描 + 生物层面跟踪 |
| 调整时机 | 通常在明显变化后 | 可能支持更早的参考调整 |
| 目标 | 遵循循证标准 | 结合个体生物特征进行个性化选择 |
在护理流程中的位置
欢迎联系我们团队，了解报告可能代表的含义及其在护理规划中的参考价值。
- Patients lived up to twice as long on average
- The cancer stayed under control for a longer period (up to 1.7x longer)
- Some patients with advanced cancer lived more than a year.
- About 4 out of 10 patients experienced their cancer shrinking or stopping from growing for a period of time
Supporting clearer,
more informed
treatment decisions
- It gives your doctor extra biological information about your cancer.
- It helps narrow down which treatments are likely to work — and which probably won’t.
- It supports clearer conversations between you, your family and your oncologist.
- Integrates standard medical care with biological information
- Supports more personalised, condition-appropriate decisions
- Helps clarify options for discussion with your oncology team
Circulating tumour cell
(CTC) analysis
Circulating tumour DNA
(ctDNA) profiling
Genomic or molecular testing
Biomarker analysis
Clinical research evaluation
Treatment Choice Can
Significantly Impact Survival
Key findings from a clinical study:
In patients with advanced cancer, about 4 out of 10 people who used a personalised cancer plan experienced their cancer shrinking or remaining stable for a period of time.
Treatment Choice Can Significantly Impact Survival
In late-stage cancer cases, targeted precision approaches have shown substantial improvement in overall survival.
Source: Precision oncology matched-therapy studies including the MD Anderson IMPACT program (Tsimberidou et al., 2017).
Genetic testing of tumors may help doctors choose more personalized treatments.
Up to 30% more lung cancer cases may be detected earlier when molecular testing is used.
Source: Selected lung cancer precision medicine studies demonstrating improved diagnosis and survival outcomes with molecular profiling (Rosell et al., 2013; Lindeman et al., 2018).
Impact of Precision Oncology
Supporting clearer, more informed treatment decisions
Cancer treatment involves many important decisions guided by clinical evaluation, imaging, pathology, and established medical guidelines.
Advances in precision medicine allow doctors to understand cancer at a biological level, adding insight that may support treatment planning and monitoring.
